Insider trade

CEO sold ~$4.17M of ROIV shares in the open market

Traded Dec 9, 2025 · Filed Dec 12, 2025

Why it stands out

The boss of Roivant Sciences sold $4.17M of Roivant Sciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$4,170,000

Shares × reported transaction price

Timing vs results

29 days after results of Nov 10, 2025, 59 days before results of Feb 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+3.6%	+0.6%	+3.0%
30 days	+8.7%	+1.4%	+7.3%
90 days	+29.1%	−1.7%	+30.9%
180 days	+37.1%	+10.9%	+26.2%

Past results only. Not a forecast.

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.